SUNNYVALE, Calif., Sept. 5 /PRNewswire/ -- CardioGenesis Corporation
(Nasdaq: CGCP), a leader in transmyocardial revascularization (TMR)
technology, today announced the appointment of E. Walter Lange to its Board of
Directors. Mr. Lange is a former Group Vice President of Marketing, Planning
and Development for Eli Lilly and Company. During his 31 years at Eli Lilly,
Mr. Lange held numerous positions, including heading the group which
orchestrated Eli Lilly and Company's entry into the medical device business.
    "We are very pleased to have Mr. Lange join our Board of Directors. He
comes to us with extensive strategic planning and corporate development
experience in the medical and medical device business. Walter's broad
knowledge of U.S. and international medical device markets coupled with his
very valuable experience with the discovery and development of new products,
will provide important strategic leadership to our business," said Allen W.
Hill, CardioGenesis's president and chief executive officer.
    Mr. Lange served as Group Vice President of Marketing, Planning and
Development for Eli Lilly and Company from 1982 to 1991. While in this
position, he was a member of senior management responsible for Worldwide
Pharmaceutical Marketing, including New Product Planning, Business Development
and Market Research/Product Management for U.S. and O.U.S. operations. From
1976 to 1981 Mr. Lange was Vice President of Marketing, Planning and
Development. This included Market Research, Product Management, and Sales
Resource Planning. From 1967 to 1975, he held the positions of Director of
Market Research, Product Manager, and District Sales Manager for the U.S.
company. Mr. Lange started with Eli Lilly and Company International in 1960 as
a Sales Representative in Canada.
    Mr. Lange graduated from the University of Wisconsin with a B.S. in
Pharmacy and received an M.B.A. from Marquette University. He currently serves
as a board member to another technology company and consults on marketing and
business development for various life science companies.
    CardioGenesis Corporation, based in Sunnyvale, California, develops,
manufactures and markets proprietary systems including disposable products, to
perform intraoperative transmyocardial revascularization (ITMR),
catheter-based percutaneous myocardial revascularization (PMR), and
thoracoscopic transmyocardial revascularization (TTMR) to treat patients
afflicted with debilitating angina. CardioGenesis(TM) probes and catheter
systems deliver laser energy to create channels in the oxygen-deprived
(ischemic) regions of the heart muscle (myocardium). CardioGenesis holds
patents for the system and method of percutaneous myocardial
revascularization, U.S. Patent Number 5,389,096; the method for intraoperative
myocardial device revascularization, U.S. Patent Number 5,380,316; and other
patents in the field of transmyocardial revascularization.  For more
information on the company and their products, visit their website at
http://www.cardiogenesis.com.
    For more information on CardioGenesis Corporation via fax, dial
800-PRO-INFO, code CGCP.

Link to this page: